Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Last trade$18.38
Day change-$0.11 (-0.59%)
Day range$18.30 – $18.93
Volume500,675
Market cap$1.31B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.31B
Price / earnings
6.79×
Price / book
1.16×
Price / sales
3×
EV / sales
2.26×
EV / EBITDA
4.71×
Profitability
Earnings per share
$2.72
Return on assets
12.58%
Return on equity
17.01%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.23×
Current ratio
15.44×
Quick ratio
14.58×
Cash ratio
11.62×
Cash flow
Price / cash flow
7.16×
Price / free cash flow
7.2×
Free cash flow
$182.51M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for INVA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$106.12M
$119.59M
$97.99M
$114.61M
$107.8M
$100.28M
$88.63M
$91.81M
Cost of revenue
$21.74M
$22.35M
$22.16M
$38.95M
$32.26M
$10.59M
$15.32M
$13.68M
Gross profit
$84.38M
$97.24M
$75.83M
$75.67M
$75.54M
$89.69M
$73.32M
$78.13M
Selling, general and administrative
$37.02M
$34.57M
$32.44M
$32.12M
$27.29M
$26.41M
$27.49M
$31.33M
Research and development
$5.21M
$5.19M
$5.24M
$4.56M
$13.67M
$7.98M
$4.4M
$3.67M
Total operating expenses
$42.23M
$46.39M
$37.68M
$36.68M
$40.96M
$40.94M
$31.89M
$34.99M
Operating income
$42.15M
$50.86M
$38.15M
$38.99M
$34.58M
$48.75M
$41.43M
$43.14M
Interest expense
-$5.47M
-$5.47M
-$5.44M
-$3.31M
-$4.02M
-$4.66M
-$4.71M
-$4.75M
Income before taxes
-$97.61M
-$108.02M
$234.56M
$195.04M
$97.82M
$72.6M
-$38.59M
$24.69M
Income taxes
-$23.72M
-$24.6M
$47.97M
$30.88M
$7.91M
$8.91M
$8M
$4.36M
Net income
-$73.89M
-$83.42M
$186.6M
$164.15M
$89.91M
$63.69M
-$46.58M
$20.33M
Net income attributable to common shareholders
-$73.89M
-$83.42M
$186.6M
$164.15M
$89.91M
$63.69M
-$46.58M
$20.33M
EBITDA
$65.57M
$47.83M
$48.2M
$49.11M
$57.71M
$45.76M
$51.39M
$53.14M
Basic earnings per share
-$1.03
-$1.14
$2.52
$2.19
$1.30
$1.01
-$0.74
$0.32
Diluted earnings per share
-$1.03
-$1.14
$2.22
$1.54
$1.08
$0.77
-$0.74
$0.23
Recent news
Company coverage with links to the original publishers.
The article identifies five stocks with low price-to-sales ratios and strong fundamentals as potential value investments: Innoviva (INVA), HF Sinclair (DINO), Par Pacific (PARR), Green Plains (GPRE), and PBF Energy (PBF). All five companies demonstrate improving margins, solid business momentum, and favorable financial metrics, making them suitable candidates for value-focused investors seeking undervalued opportunities.
Zacks identifies Innoviva (INVA) as an attractive value investment opportunity, citing its Zacks Rank #2 (Buy) rating and Value grade of A. The company trades at a P/E ratio of 10.12, significantly below its industry average of 19.36, and demonstrates favorable valuations across multiple metrics including P/S and P/CF ratios, suggesting the stock is undervalued relative to its earnings prospects.
A comparison of Innoviva (INVA) and Merck (MRK) as value investment opportunities in the large cap pharmaceuticals sector. Innoviva receives a Zacks Rank #2 (Buy) with a Value grade of A, featuring a forward P/E of 14.69 and P/B ratio of 1.21. Merck holds a Zacks Rank #3 (Hold) with a Value grade of D, showing a forward P/E of 52.92 and P/B ratio of 8.05. Based on valuation metrics and earnings revision trends, Innoviva is positioned as the better value opportunity.
Pfizer reported Q3 2026 earnings of $0.87 per share, beating consensus estimates of $0.72 by 20.83%, with revenues of $16.58 billion slightly exceeding expectations. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, and the Large Cap Pharmaceuticals industry ranks in the bottom 36% of sectors, suggesting near-term performance in line with the market.
AbbVie reported Q3 2026 earnings of $3.82 per share, beating consensus estimates of $3.74, with revenues of $17.4 billion exceeding expectations. However, the stock carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The Large Cap Pharmaceuticals industry ranks in the bottom 14% of Zacks industries. Innoviva is expected to report earnings of $0.49 per share, representing a 54.6% year-over-year decline.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Sep 8, 2015
$0.25
Sep 30, 2015
recurring
Jun 10, 2015
$0.25
Jun 30, 2015
recurring
Mar 10, 2015
$0.25
Mar 31, 2015
recurring
Nov 21, 2014
$0.25
Dec 23, 2014
recurring
Aug 26, 2014
$0.25
Sep 18, 2014
unknown
Stock splits
Historical share-structure events and their execution dates.